Further translational studies exploring the relationship between BRCA1 promoter hypermethylation and the loss/decrease in its function in terms of DNA damage in both NATs and BBLs could reinforce the potential role of BRCA1 methylation as an early biomarker for patients at risk of developing cancer, as well as the clinical application of BRCA1 promoter methylation in the management of cancerous and non-cancerous breast diseases. This evidence concerns the gene BRCA1 and cancer.